Biomarkers in the cerebrospinal fluid of patients with mild cognitive impairment: a meta-analysis of their predictive capacity for the diagnosis of Alzheimer's disease

被引:18
作者
Antonio Monge-Argiles, J. [1 ]
Sanchez-Paya, Jose [2 ]
Munoz-Ruiz, Carlos [3 ]
Pampliega-Perez, Ana [1 ]
Montoya-Gutierrez, Javier [1 ]
Leiva-Santana, Carlos [1 ]
机构
[1] Gen Hosp Univ Alicante, Serv Neurol, E-03080 Alicante, Spain
[2] Gen Hosp Univ Alicante, Serv Med Prevent, E-03080 Alicante, Spain
[3] Gen Hosp Univ Alicante, Lab Inmunol, E-03080 Alicante, Spain
关键词
Abeta-42; protein; Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Mild cognitive impairment; P-tau protein; T-tau protein; FOLLOW-UP INVESTIGATIONS; CSF-PHOSPHORYLATED-TAU; LEWY BODIES; PROTEIN; A-BETA-42; DEMENTIA; BETA-AMYLOID(1-42); CORRELATE; MARKERS; PROFILE;
D O I
10.33588/rn.5004.2009163
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Several studies have reported alterations in the cerebrospinal fluid biomarkers (Abeta-42, T-tau and P-tau proteins), both in Alzheimer's disease (AD) and in mild cognitive impairment (MCI). Aim. To perform a meta-analysis of the diagnostic yield of this technique for the prediction of patients with MCI who are going to progress to AD. Materials and methods. A search was conducted in PubMed and Embase of papers published between 1999 and September 2008, and as a result only prospective studies were included for the systematic review. The sensitivity and specificity for each biomarker were studied separately and also jointly. Results. Of the 12 studies that were included, 6 quantified the Abeta-42 protein, 11 the T-tau protein and seven the P-tau protein. In three of the studies data was obtained from the three biomarkers in combination. The sensitivity of the quantification of the T-tau and P-tau proteins is 82%, with a diagnostic odds ratio of 12.09 (confidence interval 95%, Cl 95% = 7.71-18.99; p = 0.1) and 16.29 (CI 95% = 9.69-27.4; p = 0.9), respectively. Alteration of any of the three biomarkers has a specificity of 87%, with a diagnostic odds ratio of 35.97 (CI 95% = 7.8-164.6; p = 0.04). Conclusions. The isolated alteration of T-tau or P-tau levels in cerebrospinal fluid is very sensitive for differentiating between patients with MCI who are going to develop AD and those who are going to remain stable. Normality of the three biomarkers is a very reliable way of ruling out the progression of AD in patients with MCI.
引用
收藏
页码:193 / 200
页数:8
相关论文
共 39 条
[1]   CSF biomarkers for mild cognitive impairment and early Alzheimer's disease [J].
Andreasen, N ;
Blennow, K .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2005, 107 (03) :165-173
[2]   Fluctuations of CSF amyloid-β levels -: Implications for a diagnostic and therapeutic biomarker [J].
Bateman, Randall J. ;
Wen, Guolin ;
Morris, John C. ;
Holtzman, David M. .
NEUROLOGY, 2007, 68 (09) :666-669
[3]   CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia [J].
Bibl, M ;
Mollenhauer, B ;
Esselmann, H ;
Lewczuk, P ;
Klafki, HW ;
Sparbier, K ;
Smirnov, A ;
Cepek, L ;
Trenkwalder, C ;
Rüther, E ;
Kornhuber, J ;
Otto, M ;
Wiltfang, J .
BRAIN, 2006, 129 :1177-1187
[4]   CSF markers for incipient Alzheimer's disease [J].
Blennow, K ;
Hampel, H .
LANCET NEUROLOGY, 2003, 2 (10) :605-613
[5]   Combined biomarkers for early Alzheimer disease diagnosis [J].
Borroni, Barbara ;
Premi, Enrico ;
Di Luca, Monica ;
Padovani, Alessandro .
CURRENT MEDICINAL CHEMISTRY, 2007, 14 (11) :1171-1178
[6]   Longitudinal changes of CSF biomarkers in memory clinic patients [J].
Bouwman, F. H. ;
van der Flier, W. M. ;
Schoonenboom, N. S. M. ;
van Elk, E. J. ;
Kok, A. ;
Rijmen, F. ;
Blankenstein, M. A. ;
Scheltens, P. .
NEUROLOGY, 2007, 69 (10) :1006-1011
[7]   CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment [J].
Bouwman, F. H. f ;
Schoonenboom, S. N. M. ;
van der Flier, W. M. ;
van Elk, E. J. ;
Kok, A. ;
Barkhof, F. ;
Blankenstein, M. A. ;
Scheltens, Ph .
NEUROBIOLOGY OF AGING, 2007, 28 (07) :1070-1074
[8]   Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic [J].
Brandt, Camilla ;
Bahl, Justyna C. ;
Heegaard, Niels H. H. ;
Waldemar, Gunhild ;
Johannsen, Peter .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2008, 25 (06) :553-558
[9]   Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment [J].
Brys, Miroslaw ;
Pirraglia, Elizabeth ;
Rich, Kenneth ;
Rolstad, Sindre ;
Mosconi, Lisa ;
Switalski, Remigiusz ;
Glodzik-Sobanska, Lidia ;
De Santi, Susan ;
Zinkowski, Ray ;
Mehta, Pankaj ;
Pratico, Domenico ;
Saint Louis, Leslie A. ;
Wallin, Anders ;
Blennow, Kaj ;
de Leon, Mony J. .
NEUROBIOLOGY OF AGING, 2009, 30 (05) :682-690
[10]   CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects [J].
Buerger, K ;
Teipel, SJ ;
Zinkowski, R ;
Blennow, K ;
Arai, H ;
Engel, R ;
Hofmann-Kiefer, K ;
McCulloch, C ;
Ptok, U ;
Heun, R ;
Andreasen, N ;
DeBernardis, J ;
Kerkman, D ;
Moeller, HJ ;
Davies, P ;
Hampel, H .
NEUROLOGY, 2002, 59 (04) :627-629